Acinetobacter baumannii
Jump to navigation
Jump to search
Epidemiology
- common, nosocomial, highly drug resistant, gram-negative pathogen
Pathology
- causes with pneumonia
Laboratory
Management
- imipenem/cilastin
- colistin for resistant organisms[1]
- Carbapenem-resistant Acinetobacter baumannii
- durlobactam sulbactam in combination with meropenem or imipenem-cilastatin[3]
More general terms
References
- ↑ 1.0 1.1 Journal Watch 23(13):104, 2003
Garnacho-Montero J et al Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Inect Dis 36:1111, 2003 - ↑ Centers for Disease Control and Prevention (CDC) Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb Mortal Wkly Rep. 2004 Nov 19;53(45):1063-6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15549020
- ↑ 3.0 3.1 Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024 Aug 7:ciae403. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39108079 https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae403/7728556